Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lanreotide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR5 known ✓ | P35346 | 16/20 | 1.00 |
| ▸ | SSTR2 known ✓ | P30874 | 16/20 | 1.00 |
| ▸ | SSTR3 | P32745 | 9/20 | 1.00 |
| ▸ | SSTR1 | P30872 | 3/20 | 1.00 |
| ▸ | SSTR4 | P31391 | 8/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lanreotide SCHEMBL29402091 | 1.00 | SSTR5 (1.00) | SSTR5SSTR2SSTR3SSTR1SSTR4 | |
| Lanreotide SCHEMBL19472556 | 1.00 | SSTR5 (1.00) | SSTR5SSTR2SSTR3SSTR1SSTR4 | |
| Lanreotide SCHEMBL29381700 | 1.00 | SSTR5 (1.00) | SSTR5SSTR2SSTR3SSTR1SSTR4 | |
| Lanreotide SCHEMBL29356077 | 1.00 | SSTR5 (1.00) | SSTR5SSTR2SSTR3SSTR1SSTR4 | |
| Lanreotide SCHEMBL14802383 | 1.00 | SSTR5 (1.00) | SSTR5SSTR2SSTR3SSTR1SSTR4 | |
| Lanreotide SCHEMBL19962799 | 1.00 | SSTR5 (1.00) | SSTR5SSTR2SSTR3SSTR1SSTR4 | |
| Lanreotide SCHEMBL14674691 | 1.00 | SSTR5 (1.00) | SSTR5SSTR2SSTR3SSTR1SSTR4 | |
| Lanreotide SCHEMBL21091289 | 1.00 | SSTR5 (1.00) | SSTR5SSTR2SSTR3SSTR1SSTR4 | |
| Lanreotide SCHEMBL22928940 | 1.00 | SSTR5 (1.00) | SSTR5SSTR2SSTR3SSTR1SSTR4 | |
| Lanreotide SCHEMBL28187023 | 0.99 | SSTR5 (0.99) | SSTR5SSTR2SSTR3SSTR1SSTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2796112-B2 | Degradable implantable medical devices | ELIXIR MEDICAL CORP (US) | 2023-08-09 | — | — | EP | claimed |
| US-20260144852-A1 | COMPOSITIONS AND METHODS FOR TREATING ACROMEGALY | CAMURUS AB (SE) | 2026-05-28 | — | — | US | disclosed |
| EP-4731247-A1 | COMPOSITIONS AND METHODS FOR TREATING ACROMEGALY | Camurus AB (SE) | 2026-04-29 | — | — | EP | disclosed |
| EP-4637856-B1 | VASCULAR SCAFFOLD HAVING A RARE-EARTH METAL RADIOPAQUE MARKER | MEKO MFG E K (DE) | 2026-02-25 | — | — | EP | disclosed |
| US-12472241-B2 | Treatment of respiratory disorders with arachidonate 15-lipoxygenase (ALOX15) inhibitors | REGENERON PHARMACEUTICALS, INC. (US) | 2025-11-18 | — | — | US | disclosed |
| EP-4637856-A1 | VASCULAR SCAFFOLD HAVING A RARE-EARTH METAL RADIOPAQUE MARKER | MeKo Manufacturing e.K. (DE) | 2025-10-29 | — | — | EP | disclosed |
| EP-4164674-B1 | MODULATORS OF TIGHT JUNCTION PERMEABILITY | UNIV BATH (GB) | 2025-10-22 | — | — | EP | disclosed |
| US-20250281569-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROENDOCRINE TUMORS | CAMURUS AB (SE) | 2025-09-11 | — | — | US | disclosed |
| WO-2025124355-A1 | USE OF GROWTH HORMONE INHIBITOR AND PHARMACEUTICAL COMPOSITION, FORMULATION, AND APPARATUS COMPRISING GROWTH HORMONE INHIBITOR | 中山大学中山眼科中心 | 2025-06-19 | — | — | WO | disclosed |
| WO-2025120167-A1 | VASCULAR SCAFFOLD HAVING A RARE-EARTH METAL RADIOPAQUE MARKER | MEKO MANUFACTURING E.K. (DE) | 2025-06-12 | — | — | WO | disclosed |
| US-20220378867-A1 | METHOD OF TREATING DISEASES | AMRYT PHARMACEUTICALS INC. | 2022-12-01 | — | — | US | disclosed |
| US-11510963-B1 | Method of treating diseases | AMRYT ENDO, INC. (US) | 2022-11-29 | — | — | US | disclosed |
| WO-2022235186-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROENDOCRINE TUMORS | CAMURUS AB (SE) | 2022-11-10 | — | — | WO | disclosed |
| US-20220339240-A1 | ORAL OCTREOTIDE ADMINISTERED IN COMBINATION WITH OTHER THERAPEUTIC AGENTS | AMRYT ENDO, INC. | 2022-10-27 | — | — | US | disclosed |
| CN-112773766-B | Liposome delivery system for tumor treatment and preparation method and application thereof | 暨南大学 | 2022-10-18 | — | — | CN | disclosed |
| US-11439714-B2 | Radiopharmaceutical and methods | CENTRE FOR PROBE DEVELOPMENT AND COMMERCIALIZATION (CA) | 2022-09-13 | — | — | US | disclosed |
| US-20220233630-A1 | METHOD OF TREATING DISEASES | AMRYT PHARMACEUTICALS INC. | 2022-07-28 | — | — | US | disclosed |
| US-11338011-B2 | Method of treating diseases | AMRYT ENDO, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-20220062447-A1 | RADIOPHARMACEUTICAL AND METHODS | CENTRE FOR PROBE DEVELOPMENT AND COMMERCIALIZATION (CA) | 2022-03-03 | — | — | US | disclosed |
| WO-2022043754-A2 | RADIOPHARMACEUTICAL AND METHODS | CENTRE FOR PROBE DEVELOPMENT ANDCOMMERCIALIZATION (CPDC) (CA) | 2022-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11439714-B2 | Radiopharmaceutical and methods | KIT, PROKR1, LPXN | SSTR5 4/4885SSTR2 8/4885SSTR3 10/4885 |
| US-20250281569-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROENDOCRINE TUMORS | SSTR2, SSTR5, SSTR3 | SSTR5 2/4885SSTR2 1/4885SSTR3 3/4885 |
| US-20220062447-A1 | RADIOPHARMACEUTICAL AND METHODS | KIT, PROKR1, LPXN | SSTR5 4/4885SSTR2 8/4885SSTR3 10/4885 |
| US-20260144852-A1 | COMPOSITIONS AND METHODS FOR TREATING ACROMEGALY | SSTR2, SSTR1, IGF1R | SSTR5 11/4885SSTR2 1/4885SSTR3 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.